An interventional study of active stimulation then placebo stimulation and placebo stimulation then active stimulation in Axial Spondyloarthritis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Axial Spondyloarthritis with a site in France — 9 open to participants now, 11 under way, 3 of them phase 3. Axial Spondyloarthritis · France.
Among the 40 studies in Axial Spondyloarthritis with a site in France, this one is the 20th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 24th registered.
187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.
Browse Axial Spondyloarthritis studies →9 of the 40 studies in Axial Spondyloarthritis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Association de Recherche Clinique en Rhumatologie · Sites in France
Ages 18–80
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–75
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 39 Axial Spondyloarthritis studies recruiting now, 20 (51%) set no upper age limit and 13 (33%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 13 · Phase 4 2
First in 2009; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 106 across 123 interventional studies indexed under Axial Spondyloarthritis.
Median enrollment 188 across the 30 interventional studies, 413 across the 10 observational. Of the 27 that completed or were terminated, 12 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 40 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 7 studies filed under Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
4 of the studies in Axial Spondyloarthritis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05654753Phase 3Assistance Publique - Hôpitaux de ParisThe Efficacy of Fecal Microbiota Transplatation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment | 2027-09 |
| NCT06259890Centre Hospitalier Universitaire de BesanconInfluence of Sodium Intake in spondyLoarthriTes | 2026-11 |
| NCT04286373Assistance Publique - Hôpitaux de ParisEfficacy of Non-invasive Vagus Nerve Stimulation for Axial Spondyloarthritis Resistant to Biotherapies | 2026-12 |
| NCT07141017Association de Recherche Clinique en RhumatologieInitial Standardized Global Review in Axial Spondyloarthritis | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Axial Spondyloarthritis with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to study the change in SpA disease activity, according to ASAS20 definition (Anderson et al., 2001), after 8 weeks of VNS treatment versus placebo non-specific stimulation (control group).
The secondary objectives of the Clinical Investigation are to show differences in disease evolution between the active and placebo periods of 8 weeks treatment with active VNS versus placebo VNS of the following items:
This multi-center study will be conducted in rheumatology departments of 14 public hospitals in France.
The study is part of the SMART-VNS (TM) project: a Structured Multidisciplinary Program for Advanced Research on the Therapeutic effects of Vagus Nerve Stimulation in inflammatory, infectious, neurological and painful diseases.
After informed consent, patients will be included in the Clinical Investigation by rheumatologists during routine consultations. Included patients will be randomised in two groups differing by the sequence in which the treatments are to be administered: Group A: VNS active for 8 weeks, then VNS placebo for 8 weeks; and Group B: VNS placebo for 8 weeks then VNS active for 8 weeks. In order to maintain the blind, investigators administering the stimulation will be different from those evaluating the patients, and the latter will be blinded to the treatment administered. A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ will be used in this Clinical Investigation during the active VNS periods. The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA). During the placebo VNS periods, VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Frangos et al., 2015, Fang et al., 2017). All randomized patients will be followed up until the end of their stimulation periods. Data collection for the assessment of endpoints will be performed by biochemistry tests and questionnaires in all patients at the first and the last visit of each period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VNS active stimulation: Use of device (Tens Eco Plus SCHWA MEDICO™) for 8 weeks, then VNS placebo for 8 weeks. The two stimulation periods will be separated by a 4 +/- 1 weeks wash-out period. The VNS placebo stimulation period being the control one.
Device: active stimulation then placebo stimulation
VNS placebo for 8 weeks, then VNS active stimulation Use of device (Tens Eco Plus SCHWA MEDICO™) for 8 weeks. The two stimulation periods will be separated by a 4 +/- 1 weeks wash-out period. The VNS placebo stimulation period being the control one.
Device: placebo stimulation then active stimulation
The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient. A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation. VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015). The two stimulation periods will be separated by a 4 weeks wash-out period.
VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015). The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient. A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation. The two stimulation periods will be separated by a 4 weeks wash-out period.
Change according to the ASAS Response Criteria (ASAS 20)
Assessement of efficacy of VNS treatment: for SpA patients under VNS treatment and under placebo non-specific stimulation, to demonstrate improvement of VNS treatment, according to ASAS20 definition, greater than placebo non-specific stimulation. ASAS20 Response is defined as follows: an improvement of 20% compared to baseline and an absolute improvement from baseline of at least 1 unit, in 3 of the 4 ASAS domains: as well as no baseline deterioration of 20% and of at least one unit in the fourth domain.
Time frame: At baseline and week 12
Improvement according to "ASAS40" criteria
A 40% improvement "ASAS40" after VNS treatment
Time frame: at baseline, 3 months, 4 months ans 7 months
Partial remission
Partial remission according to the ASAS definition
Time frame: at baseline, 3 months, 4 months ans 7 months
Improvement of BASFI
Time frame: at baseline, 3 months, 4 months ans 7 months
Serum CRP level
Changes of C-reactive protein (CRP) serum level
Time frame: at baseline, 3 months, 4 months ans 7 months
Serum ESR
Changes of serum erythrocytes sedimentation rate (ESR)
Time frame: at baseline, 3 months, 4 months ans 7 months
ASDAS_CRP
Changes of ASDAS_CRP
Time frame: at baseline, 3 months, 4 months ans 7 months
ASDAS_ESR
Changes of ASDAS_ESR
Time frame: at baseline, 3 months, 4 months ans 7 months
Circulating cytokines level of IL-6, IL-17, IL-23, IL-33, and MMP-3-8-9
Difference in levels of circulating cytokines: IL-6, IL-23,IL-17, IL-33 and of matrix metallopeptidases (MMP3-8-9)
Time frame: at baseline, 3 months, 4 months ans 7 months
Quality of life: SF-36
Assessement of quality of life: according to the following indexes: SF-36
Time frame: at baseline, 3 months, 4 months ans 7 months
Quality of life: AS Quality of Life (ASQOL)
Assessement of quality of life: according to the AS Quality of Life (ASQOL).
Time frame: at baseline, 3 months, 4 months ans 7 months
ASAS-HI
Change of Health Index of patient with SpA (ASAS HI)
Time frame: at baseline, 3 months, 4 months ans 7 months
WPI Productivity Index
Change of Health Index of patient with the WPI Productivity Index
Time frame: at baseline, 3 months, 4 months ans 7 months
Fatigue severity evaluation
A visual analogue scale (VAS) will be used to evaluate fatigue severity
Time frame: at baseline, 3 months, 4 months ans 7 months
Global Pain assessment
Global Pain assessment will be used.
Time frame: at baseline, 3 months, 4 months ans 7 months
Anxiety and Depression Assessment
Anxiety and Depression Assessment : HAD
Time frame: at baseline, 3 months, 4 months ans 7 months
BASMI
Time frame: at baseline, 3 months, 4 months ans 7 months
Non-steroidal anti-inflammatory drugs (NSAID) intake score
Change of non-steroidal anti-inflammatory drugs (NSAID) intake score
Time frame: at baseline, 3 months, 4 months ans 7 months
Plan to share: No
Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.
Of 46 non-industry interventional studies with no phase under Axial Spondyloarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 15 months is below that.
Counting every sponsor, half of 46 studies reached it within 28 months; a quarter within 11 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →